A $4B life-sciences merger clears the regulators

The Client — A US-listed therapeutics company with a multi-asset oncology pipeline, pursuing the strategic acquisition of a European peer whose programs overlapped in two priority indications.

The Situation — The transaction triggered second requests from both the FTC and the European Commission. Both regulators flagged early-stage pipeline overlap as a competitive concern, with EU staff signaling that divestiture of one program would likely be required for clearance.

The Challenge — The contested overlap covered the two assets that drove the deal's strategic rationale. A traditional divestiture would have unwound the central value of the acquisition while leaving the client exposed to integration risk on the assets it retained.

What We Did — Rather than negotiate divestitures up front, the team pressed a fix-it-first approach with internal restructuring of the early-stage portfolio — a position usually reserved for marketed products. Coordinated submissions to both reviewers preserved a unified competitive narrative across jurisdictions, and the client's economists produced parallel models calibrated to each regulator's framework.

The Results — Both regulators cleared the transaction without remedies. The deal closed on its original timetable, and the client retained the contested pipeline assets that were central to the strategic rationale of the acquisition.